Yuhua Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuhua Feng has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chunhong Hu
Deparment of Oncology, Second Xiangya Hospital, Changsha 410011, China
2 shared publications- Hui Zhou
Department of Lymphoma & Hematology The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Cancer Hospital Changsha China
2 shared publications Jie Ling
Deparment of Oncology, Second Xiangya Hospital, Changsha 410011, China
2 shared publicationsXianling Liu
Deparment of Oncology, Second Xiangya Hospital, Changsha 410011, China
2 shared publicationsYangchun Xie
Deparment of Oncology, Second Xiangya Hospital, Changsha 410011, China
2 shared publications- Chao Deng
Deparment of Oncology, Second Xiangya Hospital, Changsha 410011, China.
1 shared publication
Latest Publications
- Open Access
- 28 December 2024
- Vol. 49 (12) , 1909-1918
Prognostic value of pretreatment peripheral blood hemoglobin×lymphocyte/monocyte ratio in patients with nasopharyngeal carcinoma.
Peripheral whole blood cell counts have been used as prognostic indicators for various cancers, but their predictive value in nasopharyngeal carcinoma remain unclear. This study aims to evaluate the prognostic significance of the pretreatment hemoglobin×lymphocyte/monocyte ratio (HLMR) in non-recurrent, non-metastatic NPC patients undergoing definitive radiotherapy. Clinical and follow-up data from 805 NPC patients who completed definitive radiotherapy or chemoradiotherapy were retrospectively analyzed. Pretreatment hemoglobin, lymphocyte count, and monocyte count were collected to calculate HLMR. Receiver operating characteristic (ROC) curves were used to determine the optimal cut-off value of HLMR. Patients were then classified into high and low HLMR groups. The association between HLMR and clinicopathological characteristic was assessed using chi-square tests. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using Cox proportional hazards models. A nomogram was constructed based on the independent predictors to estimate patient survival rates, and internal validation was performed using a validation cohort. The ROC curve identified 605.5 as the optimal HLMR cut-off value for predicting 5-year survival. Multivariate Cox regression analysis revealed that T stage (HR=1.886, 95% CI 1.331 to 2.673, PHR=2.021, 95% CI 1.267 to 3.225, P=0.003), Eastern Cooperative Oncology Group (ECOG) score (HR=3.991, 95% CI 1.257 to 12.677, P=0.019), concurrent chemoradiotherapy regimen (HR=0.338, 95% CI 0.156 to 0.731, P=0.006), and HLMR (HR=0.648, 95% CI 0.460 to 0.912, P=0.013) were independent prognostic factors for OS. A nomogram including T stage, N stage, and HLMR in the training cohort was constructed to predict 3-, 5-, and 7-year OS, with a C-index of 0.713. The area under the curves for predicting 3-, 5-, and 7-year OS were 0.744, 0.665, and 0.682, respectively. Calibration curves showed good agreement between predicted and observed survival rates. The above results were further confirmed in the validation cohort. Pretreatment HLMR may serve as a promising prognostic biomarker for patients with nasopharyngeal carcinoma.
- 28 December 2024
- Vol. 49 (12) , 1909-1918
Open AccessPrognostic value of pretreatment peripheral blood hemoglobin×lymphocyte/monocyte ratio in patients with nasopharyngeal carcinoma.
Peripheral whole blood cell counts have been used as prognostic indicators for various cancers, but their predictive value in nasopharyngeal carcinoma remain unclear. This study aims to evaluate the prognostic significance of the pretreatment hemoglobin×lymphocyte/monocyte ratio (HLMR) in non-recurrent, non-metastatic NPC patients undergoing definitive radiotherapy. Clinical and follow-up data from 805 NPC patients who completed definitive radiotherapy or chemoradiotherapy were retrospectively analyzed. Pretreatment hemoglobin, lymphocyte count, and monocyte count were collected to calculate HLMR. Receiver operating characteristic (ROC) curves were used to determine the optimal cut-off value of HLMR. Patients were then classified into high and low HLMR groups. The association between HLMR and clinicopathological characteristic was assessed using chi-square tests. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using Cox proportional hazards models. A nomogram was constructed based on the independent predictors to estimate patient survival rates, and internal validation was performed using a validation cohort. The ROC curve identified 605.5 as the optimal HLMR cut-off value for predicting 5-year survival. Multivariate Cox regression analysis revealed that T stage (HR=1.886, 95% CI 1.331 to 2.673, PHR=2.021, 95% CI 1.267 to 3.225, P=0.003), Eastern Cooperative Oncology Group (ECOG) score (HR=3.991, 95% CI 1.257 to 12.677, P=0.019), concurrent chemoradiotherapy regimen (HR=0.338, 95% CI 0.156 to 0.731, P=0.006), and HLMR (HR=0.648, 95% CI 0.460 to 0.912, P=0.013) were independent prognostic factors for OS. A nomogram including T stage, N stage, and HLMR in the training cohort was constructed to predict 3-, 5-, and 7-year OS, with a C-index of 0.713. The area under the curves for predicting 3-, 5-, and 7-year OS were 0.744, 0.665, and 0.682, respectively. Calibration curves showed good agreement between predicted and observed survival rates. The above results were further confirmed in the validation cohort. Pretreatment HLMR may serve as a promising prognostic biomarker for patients with nasopharyngeal carcinoma.
- Open Access
Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients
- Open Access
- 17 May 2022
- Published by Springer Nature in Research Square
Dynamic Peripheral Blood Lymphocyte Subsets as Predictive Biomarkers for Langerhans Cell Histiocytosis in Children
Background: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm, immune system dysfunction may attribute to the cause of LCH. There is no standard prognosis evaluation system for LCH in children. We investigated the prognosis predictive value of peripheral lymphocyte subsets in childhood LCH patients.Methods: A cohort of 79 childhood LCH patients was retrospectively studied. The prognosis predictive significance of CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells, B cells and CD4/CD8 ratio were analyzed.Results: After 6-week induction therapy, the percentage of CD3+ T cells, CD3+CD4+ T cells and CD4/CD8 ratio were significantly increased, while CD3+CD8+ T cells and B cells were decreased. CD3+CD8+ T cells and B cells were closely related to BRAF V600E and MAP2K1 mutation. ∆CD3+ T cells, ∆CD3+CD4+ T cells, ∆CD3+CD8+ T cells, ∆NK cells and ∆B cells were related to treatment efficacy. As for organ involvements, ∆CD3+ T cells and ∆CD3+CD8+ T cells were related to liver involvement, ∆CD4/CD8 ratio was related to CNS involvement ∆CD3+ T cells and ∆B cells were related to BRAF V600E mutation, while ∆CD3+CD4+ T cells was related to MAP2K1 mutation. Furthermore, increased ∆CD3+ T cells, decreased ∆CD3+CD4+ T cells, decreased ∆CD3+CD8+ T cells, decreased ∆NK cells and increased ∆B cells were predictors for superior PFS, while increased ∆CD3+ T cells, decreased ∆CD3+CD8+ T cells and decreased ∆NK cells were predictors for superior OS. In addition, multivariate Cox regression analysis showed that ∆CD3+ T cells and ∆CD3+CD8+ T cells were independent prognostic factors for PFS.Conclusions: The peripheral lymphocyte subsets including CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells and B cells might be promising predictive indicators for LCH in children.
- 17 May 2022
- Published by Springer Nature in Research Square
Open AccessDynamic Peripheral Blood Lymphocyte Subsets as Predictive Biomarkers for Langerhans Cell Histiocytosis in Children
Background: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm, immune system dysfunction may attribute to the cause of LCH. There is no standard prognosis evaluation system for LCH in children. We investigated the prognosis predictive value of peripheral lymphocyte subsets in childhood LCH patients.Methods: A cohort of 79 childhood LCH patients was retrospectively studied. The prognosis predictive significance of CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells, B cells and CD4/CD8 ratio were analyzed.Results: After 6-week induction therapy, the percentage of CD3+ T cells, CD3+CD4+ T cells and CD4/CD8 ratio were significantly increased, while CD3+CD8+ T cells and B cells were decreased. CD3+CD8+ T cells and B cells were closely related to BRAF V600E and MAP2K1 mutation. ∆CD3+ T cells, ∆CD3+CD4+ T cells, ∆CD3+CD8+ T cells, ∆NK cells and ∆B cells were related to treatment efficacy. As for organ involvements, ∆CD3+ T cells and ∆CD3+CD8+ T cells were related to liver involvement, ∆CD4/CD8 ratio was related to CNS involvement ∆CD3+ T cells and ∆B cells were related to BRAF V600E mutation, while ∆CD3+CD4+ T cells was related to MAP2K1 mutation. Furthermore, increased ∆CD3+ T cells, decreased ∆CD3+CD4+ T cells, decreased ∆CD3+CD8+ T cells, decreased ∆NK cells and increased ∆B cells were predictors for superior PFS, while increased ∆CD3+ T cells, decreased ∆CD3+CD8+ T cells and decreased ∆NK cells were predictors for superior OS. In addition, multivariate Cox regression analysis showed that ∆CD3+ T cells and ∆CD3+CD8+ T cells were independent prognostic factors for PFS.Conclusions: The peripheral lymphocyte subsets including CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells and B cells might be promising predictive indicators for LCH in children.
- Open Access
- 1 November 2019
- Published by Elsevier in Translational Oncology
- Vol. 12 (11) , 1496-1503
Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis
- 1 November 2019
- Published by Elsevier in Translational Oncology
- Vol. 12 (11) , 1496-1503
Open AccessPrognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis
- 1 June 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 488 (1) , 182-188
STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback
- 1 June 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 488 (1) , 182-188
STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback